Introduction: Patients with chronic lymphocytic leukemia (CLL) are highly vulnerable to infections owing to persistent immune dysfunction, leading to an increased risk of severe disease and ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Suchitra Sundaram, MD, shares that ASH 2025 presented major advances in chronic lymphocytic leukemia (CLL) across both time‑limited and continuous treatment strategies, and emphasized the growing role ...